Zusammenfassung
Das Harnblasenkarzinom ist ein häufig diagnostizierter maligner Tumor mit einer weltweit ansteigenden Neuerkrankungsrate. Während die globale Inzidenz mit 261.000 angenommen wird, versterben jährlich etwa 115.000 Menschen an dieser Erkrankung [43].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
American Society of Clinical Oncology (1994) Recommendations for the use of hematopoitic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 12: 2471–2508
American Society of Clinical Oncology (1996) Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 14:1957–1960
Anonymous: Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscleinvasive bladder cancer: a randomized controlled trial. Lancet 354:533–540, 1999
Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, Boyle MG: Long-term survival in metastatic transitional — cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173–3181, 1999
Becker N, Wahrendorf J: Krebsatlas der Bundesrepublik Deutschland. 1981–1990.3.Auflage. Springer, Berlin (1997)
Bellmunt J, Guillem V, Paz-Ares L et al.: Phase I/II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol 18:3247–3255, 2000
Böhle A, Block Th, Jakse G, Otto Th, Hofstädter F: Harnblasenkarzinom. In: Weißbach L, Miller K (Hrsg.): Qualitätssicherung in der Onkologie. Diagnostische und therapeutische Standards in der Urologischen Onkologie. W.Zuckschwerdt Verlag; S.30–64, 1998
Bono AV, Benvenuti C, Reali L, Pozzi E, Gibba A, Cosciani-Cunico S, Comuzzi U, Anselmo G: Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group. Prog Clin Biol Res 303:533–540, 1989
Boutan Laroze A, Mahjoubi M, Droz JP: M-VAC for advanced carcinoma of the bladder. The French Federation of Cancers Centers experience. Eur J Cancer 27:1690–1694, 1991
Broome CM, Hussain M, Gutheil J: Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. Proc Amer Soc Clin Oncol 19:351a (abstract.1381), 2000
Cohen MH, Rothmann M: Gemcitabine and cisplatin for advanced, metastatic bladder cancer. J Clin Oncol 19:1229–1231, 2001
de Mulder PH, Debruyne FM, Keizer HJ, Ten Bokkel Huinick W, de Pauw M, Sylvester R: Randomized phase II study of methotrexate (M), cisplatin (C) and methotrexate, cisplatin and vinblastine (V) in patients with advanced transitional carcinoma of the bladder. Eur Urol 18 [Suppl.1] :5,1990
de Wit R, Tesselaar M, Kok TC: Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer. Eur J Cancer 27:1383–1385, 1991
de Wit R, Kaye SB, Roberts JT: Oral piritrexim, an effective treatment for metastatic urothelial cancer. Br J Cancer 67:388–390, 1993
de Wit R, Kruit WH, Stoter G: Docetaxel (Taxotere): An active agent in metastatic urothelial cancer-results of a phase II study in nonchemotherapy — pretreated patients. Br J Cancer 78:1342–1345, 1998
Freiha F, Reese J, Torti FM: A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155:495–499, 1996
Gebbia V, Testa A, Borsellino N, Mauceri G, Varvara F, Tirritio Ml, Sambataro D, Fallica G: Single agent 2′, 2′-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma:a phase II study. Clin Ter 150:11–15, 1999
Hautmann RE, Miller K, Steiner U: The ileal neobladder: 6 years of experience with more than 200 patients. J Urol 150:40–45, 1993
Henly DR, Farrow GM and Zincke H: Urachal cancer: role of conservative surgery. Urology 42:635–639, 1993
Herr HW: Urachal carcinoma: the case for extended partial cystectomy. J Urol 151:365–366, 1994
Hillcoat BL, Raghavan D, Matthews J: A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of urothelial tract. J Clin Oncol 7:706–712, 1989
Igawa M, Ohkucki T, Ueki T: Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 144:662–665, 1990
Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W, Stadler W: Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18:1921–1927, 2000
Khandekar JD, Elson PJ, de Wys WD, Slayton RE, Harris DT: Comparative activity and toxicity of cis-diaminedichloroplatinum in disseminated transitional cell carcinoma of the urinary tract. J Clin Oncol 3:539–549, 1985
Khorsand M, Lange J, Feun L: Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. Proc Amer Soc Clin Oncol 15:297 (abstr.821), 1996
Kunze E: Formale Pathogenese des Harnblasenkarzinoms. In: Bichler K.-H., Wilbert D, Wechsel HW, Strohmaier WL: Diagnostik und Therapie des Harnblasenkarzinoms. Einhorn Presseverlag 1998
Llado A, Bellmunt J, Kaiser G, Baselga J: A dose finding study of carboplatin with fixed doses of gemcitabine in “unfit” patients with advanced bladder cancer. Proc Amer Soc Clin Oncol 19:344a, 2000
Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, StuartHarris R, Sarosdy MF, Lowe BA: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066–1073, 1992
Logothetis CJ, Johnson DE, Chong C, Dexeus FH, Sella A, Ogden S, Smith T, Swanson DA, Babaian RJ, Wishnow KI: Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 6:1590–1596, 1988
Logothetis CJ, Dexeus FH, Finn L: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050–1055, 1990
Logothetis C, Swanson D, Amato R, Banks M, Finn L, Ayala AG, Ro J, Babaian R, Dinney C, Ellerhorst J, Hall C, von Eschenbach A: Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. J Urol 155:1241–1245, 1996
Lorusso V, Manzione L, De Vita F,Antimi M, Selvaggi FP, De Lena: Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol 164:53–56, 2000
Malkowicz SB, Nichols P, Lieskovsky G, Boyd SD, Huffman J, Skinner DG: The role of cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS, and P2). J Urol 144: 641–645,1990
Malmstrom PU, Rintala E, Wahlquist R, Hellstrom P, Nilsson S, Hellsten S, Hannisdal E: Five year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy. J Urol 155:1903–1906, 1996
Malmstrom PU, Rintala E, Wahlquist R, Hellstrom P, Nilsson S, Hellsten, and members of the Nordic Urothelial Cancer Group: Neoadjuvant cisplatin-methotrexate chemotherapy of invasive bladder cancer. Nordic cystectomy trial 2. Eur Urol 35 (Suppl 12):60 (abstract 238), 1999
Mathur VK, Krahn HP, Ramsey E: Total cystectomy for bladder cancer. J Urol 125:784–788, 1981
McCaffrey JA, Hilton S, Mazumdar M: Phase II trial of docetaxel in patients with advanced or metastatic transitional — cell carcinoma. J Clin Oncol 15:1853–1857, 1997
Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N: Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15:3441–3445, 1997
Moore MJ, Winquist EW, Murray N, Tannock IF, Huan S, Bennett K, Walsh W, Seymour L: Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17:2876–2881, 1999
Natale RB, Grossmann HB, Blumenstein B, Vogelzang N, Trump DL, Speights VO, de Vere White R, Crawford ED (2001): SWOG 8710 (INT-0080): Randomized Phase III Trial of Neoadjuvant MVAC + Cystectomy versus Cystectomy alone in patients with locally advanced Bladder Cancer. Plenary Presentation. Proc Amer Soc Clin Oncol 20:2a.
Nogue M, Carles J, Arrivi A, Garrido P: Palliative chemotherapy with gemcitabine and carboplatin in advanced transitional cell carcinoma of the urothelium — preliminary results. Proc Amer Soc Clin Oncol 19:345a
Papamichael D, Gallagher CJ, Oliver RT: Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 75:606–607, 1997
Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 49:33–64, 1999
Pollera CF, Ceribelli A, Crecco M, Calabresi F: Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 5:182–184, 1994
Raghavan D, Shipley WU, Garnick MD: Biology and management of bladder cancer. New Engl J Med 322:1129–1138 (1990)
Roehrborn CG, Sagalowsky AI, Peters PC: Long-term patient survival after cystectomy for regional metastatic transitional cell carcinoma of the bladder. J Urol 146:36–39
Roth BJ, Dreicer R, Einhorn LH: Significant activity of paclitaxel in advanced transitional -cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12:2264–2270, 1994
Santoro A, Santoro M, Maiorino L, Forestieri V, Forestieri P: Phase II trial of gemcitabine plus carboplatin for urothelial transitional cell carcinoma in advanced or metastatic stage. Ann Oncol 9:169, 1998
Skinner DG: Current perspectives in the management of high-grade invasive bladder cancer. Cancer 45(Suppl.7):1866–1874, 1980
Skinner DG, Lieskovsky G: Contemporary cystectomy with pelvic lymph node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J Urol 131:1069–1075, 1984
Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, Kern W, Sakamoto J, Krailo M, Groshen S: The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 145:459–464, 1991
Solsona E, Iborra I, Ricos JV, Monros JL, Dumont R: Feasibility of transurethral resection for muscle-infiltrating carcinoma of the bladder: prospective study. J Urol 147:1513–1515, 1992
Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394–3398, 1997
Sternberg CN, Yagoda A, Scher HI: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133:403–407, 1985
Sternberg CN, Yagoda A, Scher HI: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 64:2448–2458, 1989
Sternberg CN, Scher HL: Management of invasive bladder neoplasm. In: Smith PH: Combination therapy in urological malignancy. London, Springer Verlag :95–118,1989
Sternberg CN: The treatment of advanced bladder cancer. Ann Oncol 6:113–126,1995
Sternberg CN, de Mulder PH, Schornagel J, Theodore C, Fossa SD, Tirelli U, van Groeningen CJ, Colette L: Randomized phase III trial in advanced urothelial tract tumours of high dose intensity M-VAC chemotherapy and G-CSF versus classic MVAC. Proc Am Soc Clin Oncol 19: 1292 a, 2000
Sternberg CN, Calabro F: Neo-adjuvant chemotherapy in invasive bladder cancer. World J Urol 19:94–98, 2001
Stoeckle M, Meyenburg W, Wellek S, Voges GE, Rossmann M, Gertenbach U, Thüroff JW, Huber C, Hohenfellner R: Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 153:47–52, 1995
Stoeckle M, Meyenburg W, Wellek S, Voges GE, Fischer U, Gertenbach U, Thüroff JW, Huber C, Hohenfellner R: Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology 48:868–875, 1996
Stoter G: Chemotherapy for metastatic bladder carcinoma. World J Urol 3:110–119, 1985
Studer UE, Bacchi M, Biedermann C, Jaeger P, Kraft R, Mazzucchelli L, Markwalder R, Senn E, Sonntag RW: Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 152:81–84, 1994
Tannock I, Gospodarowicz M, Connoly J: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. J Urol 142:289–292, 1989
Thrasher JB and Crawford ED: Current management of invasive and metastatic transitional cell carcinoma of the bladder. J Urol 149:957–972, 1993
Vaishampayan UN, Smith DC, Dickow B, Hussain M: Carboplatin, paclitaxel, and gemcitabine in advanced urothelial carcinoma: updated results. Proc Amer Soc Clin Oncol 19:341a, 2000
von der Maase H, Andersen L, Crino L, Weinknecht S, Dogliotti L: Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol 10: 1461–1465,1999
von der Maase H, Hansen SW, Roberts PF, Oliver T, Moore M: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 17: 3068–3077,2000
Yagoda A: Chemotherapy of urothelial tract tumors. Cancer 60:574–585, 1987
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Machtens, S., Schöffski, P., Kuczyk, M. (2002). Pharmakologische Therapie des lokal fortgeschrittenen und metastasierten Harnblasenkarzinoms. In: Truss, M.C., Stief, C.G., Machtens, S., Jonas, U., Wagner, T. (eds) Pharmakotherapie in der Urologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-09273-6_2
Download citation
DOI: https://doi.org/10.1007/978-3-662-09273-6_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-41519-0
Online ISBN: 978-3-662-09273-6
eBook Packages: Springer Book Archive